Myriad Genetics, Inc.
MYGNNASDAQHealthcare● Active
$4.42
$-0.16(-3.39%)
Market Cap$416988803
P/E Ratio—
52W High$8.59
52W Low$3.53
Myriad Genetics, Inc. (MYGN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MYGN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.82B | $0.84B | $0.75B | $0.68B | $0.69B |
| Cost of Revenue | $0.25B | $0.25B | $0.24B | $0.20B | $0.20B |
| Gross Profit | $0.58B | $0.59B | $0.52B | $0.48B | $0.49B |
| Gross Margin %(computed) | 69.93% | 69.89% | 68.64% | 70.22% | 71.39% |
| Operating Expenses | |||||
| R&D Expenses | $0.11B | $0.11B | $0.09B | $0.09B | $0.08B |
| G&A Expenses | $0.26B | $0.28B | $0.28B | $0.25B | $0.54B |
| Total Operating Expenses | $0.64B | $0.71B | $0.77B | $0.62B | $0.68B |
| Operating Income | ($0.07B) | ($0.12B) | ($0.26B) | ($0.14B) | ($0.19B) |
| Operating Margin %(computed) | -8.22% | -14.74% | -34.17% | -20.73% | -27.58% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.00B | $0.00B | $0.00B | $0.01B |
| Income Before Tax | ($0.40B) | ($0.12B) | ($0.26B) | ($0.14B) | ($0.06B) |
| Income Tax Expense | ($0.03B) | $0.00B | $0.00B | ($0.03B) | ($0.03B) |
| Net Income | ($0.37B) | ($0.13B) | ($0.26B) | ($0.11B) | ($0.03B) |
| Net Margin %(computed) | -44.38% | -15.20% | -34.96% | -16.51% | -3.94% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.96 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
| Wtd Avg Shares | 0.09B | 0.09B | 0.08B | 0.08B | 0.08B |
| EBITDA | ($0.33B) | ($0.06B) | ($0.20B) | ($0.08B) | $0.01B |
| EBITDA Margin %(computed) | -40.13% | -7.10% | -26.21% | -12.49% | 1.78% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Myriad Genetics, Inc. data
About Myriad Genetics, Inc. (MYGN) Income Statement
Myriad Genetics, Inc. (MYGN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MYGN reported revenue of $0.82B, gross profit of $0.58B (gross margin 69.93%), and net income of ($0.37B) — a net profit margin of -44.38%.
Frequently asked questions
MYGN · 4 questionsMyriad Genetics, Inc. (MYGN) reported revenue of $0.82B for 2025, down 1.6% year-over-year.
MYGN revenueMYGN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08